By Jonathan Stempel

NEW YORK (Reuters) – Pfizer (NYSE:) will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT, the U.S. Department of Justice said on Friday.

The Justice Department said that from March 1, 2020, to Sept. 30, 2022, Biohaven Pharmaceuticals violated the federal False Claims Act by providing speaker honoraria and meals at high-end restaurants to doctors, to induce them to prescribe Nurtec more often.

According to the government, some speaker programs were attended multiple times by the same doctors, resulting in no educational benefit, or attended by doctors’ spouses, family members and colleagues who had no educational need to be there.

Pfizer ended the Nurtec speaker programs after paying $11.5 billion to buy Biohaven in October 2022.

“Patients deserve to know that their doctor is prescribing medications based on their doctor’s medical judgment, and not as a result of financial incentives from pharmaceutical companies,” said Trini Ross, U.S. Attorney for the Western District of New York.

Pfizer did not admit wrongdoing in agreeing to settle.

“We are pleased to put this legacy matter behind us, so that we can continue to focus on the needs of patients,” the New York-based drugmaker said in a statement.

The settlement resolves an August 2021 lawsuit filed in the Rochester, New York federal court by Patricia Frattasio, a former Biohaven neuroscience sales specialist.

© Reuters. FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo

She will receive about $8.4 million from the settlement. About $41.8 million will go to the federal government and $9.5 million will go to state Medicaid programs.

The False Claims Act lets whistleblowers sue on behalf of the government, and share in recoveries.


Source link

Best Brokers

Unmatched trading fees, generous bonuses, top notch Regulation Frame.

T&Cs Apply

Risk disclosure: All investments involve a degree of risk of some kind. Trading financial derivative products comes with a high risk of losing money rapidly due to leverage.

Top-Tier Regulations. Unmatched Spreads and Commissions. Trading View is available.

T&Cs Apply

Financial Spread Trades and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84.7% of retail investor accounts lose money when trading CFDs with this provider.

Modern and Intuitive Interfaces, Solid Regulatory Frame, and excellent Trading Fees.

T&Cs Apply
Risk warning: Trading derivatives is highly speculative, carries an inherent risk of loss and is not suitable for all investors. Before trading, you are strongly advised to read and ensure that you understand the relevant risk disclosures and warnings.

Highly Regulated. Low Spreads and Commissions. Vast Account Options.

T&Cs Apply

Risk Warning: Trading derivatives carries significant risks. It is not suitable for all investors and if you are a professional client, you could lose substantially more than your initial investment.